Ongoing projects
Research Project Title |
Acronym |
Data controller |
Lawfulness of processing |
Recipients of the data |
Data retention period |
Category of data |
Transfer outside the EU |
|---|---|---|---|---|---|---|---|
Matching of the FREGAT clinical and biological database with the SNDS |
FREGAT-Link |
CHU de Lille |
Public interest |
Academic |
3 years after completion of research |
Clinical data |
No |
Role of socioeconomic and environmental inequalities on esogastric cancers |
INEKOG |
Lille university, UMR CNRS 9221 |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Understanding the molecular mechanisms associated with tumor resistance in gastric adenocarcinoma |
miniPRESTO |
Institut régional du cancer de Montpellier |
Public interest |
Academic |
Completion of research |
Clinical data – Tumour samples |
No |
Biological analyses and response to therapy of esogastric adenocarcinomas with microsatellite instability |
ARTEMSI |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data – Tumour samples |
No |
MS Guide surgery for gastric cancer |
MS Guide |
Lille university / INSERM U1192 |
Public interest |
Academic |
Completion of research |
Clinical data – Tumour samples |
No |
Development of a statistical model for the prediction of MSI status from digitized H&E slides of tumor tissue |
MSI-IA |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data – Tumour samples |
No |
Using artificial intelligence to predict the molecular subtype and oncologic outcome of patients with adenocarcinoma of the stomach |
FREGANET |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data – Tumour samples |
No |
Using artificial intelligence to predict the molecular subtype and oncologic outcome of patients with esophageal adenocarcinoma |
FREGATIA |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data – Tumour samples |
No |
The presence of metastatic lymph nodes in esogastric adenocarcinoma: a definitive contraindication to surgery? |
OMEGA |
Association pour l’étude des maladies digestives |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Effects of centralization of cancer care on patients' quality of life. Analysis and perspectives from the FREGAT cohort (oesogastric cancers). |
CENTRAVIE |
Centre Léon Bérard |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Disease burden, epidemiology, treatment patterns and healthcare resource utilization in France for locally advanced unresectable or metastatic adenocarcinoma of gastric and gastroesophageal Junction (G/GEJ): an analysis using the FREGAT Database |
BECOME |
Astellas |
Public interest |
Industrial |
Completion of research |
Clinical data |
No |
Feasibility and efficacy of perioperative treatment in patients over 75 years managed for localized adenocarcinoma of the stomach or GEJ. |
STOMAGE |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Defining Predictive Immunedeterminants of response to neoadjuvant Chemoradiation in Oesophageal adenocarcinoma. |
PREDICO |
San Raffaele Scientific Institute (Italy) |
Public interest |
Academic |
Completion of research |
Clinical data – Biopsies - Blood samples |
No |
Dissecting metabolic heterogeneity in oesophageal cancer to increase immunotherapy efficacy and overcome resistance |
IMPROVE |
Institut Pasteur Lille |
Public interest |
Academic |
Completion of research |
Clinical data – Biopsies |
No |
Real world management and outcomes of patients with non-metastatic esophageal squamous cell carcinoma in the FREGAT database |
2024-01 |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Determination of microbiological factors predictive of response to neoadjuvant therapy in non-metastatic esophageal adenocarcinoma and esogastric junction |
MICADOE |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Circulating biomarker signatures for the detection of preneoplastic lesions and gastric cancer. |
PREGASIGN |
Institut Pasteur |
Public interest |
Academic |
Completion of research |
Clinical data - Blood samples |
No |
EBV + and Gastric Cancer |
EBV Estomac |
Association des Gastroentérologues Oncologues (AGEO) |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Evaluation of the administration of artificial nutrition by feeding jejunostomy during neoadjuvant treatment on postoperative morbidity in the context of esophageal or gastric cancer |
FREJENO |
CHU de Bordeaux |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |
Prediction of severe postoperative complications after esogastric surgery using deep learning models, applied to the national FREGAT database |
PREDICT-EGS |
Laboratoire SYNERGIES |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |
Mode of onset of peritoneal carcinomatosis in gastric cancers in Lille over 10 years and selection for surgery |
GASTRILILLE |
CHU de Lille |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |
Postoperative and oncological outcomes of the minimally invasive approach in gastric cancer in France: a retrospective comparative study from the FREGAT database (based on a composite endpoint: TEXTBOOK outcome) |
TEXTBOOK outcome |
CHU de Lille |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |
Validation of a predictive calcium score for the risk of anastomotic leak after oncological esophageal surgery |
OESOCALCISCORE |
CHU de Limoges |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |
Evaluation of the evolution of quality of life during the surgical management of cardia cancers – Trajectory and Impact on Quality of life in Oesogastric cancer over time |
TIME-QOG |
AP-HP |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |
Characterization of the Response Evaluated by transcriptomic Signatures for Chemotherapies and Immunotherapies in esogastric Adenocarcinoma. |
CRESCENDO |
CHU de Lille |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |
SarcopenIa in Gastric cancer iMpact Assessment |
SIGMA |
CHU de Rennes |
Public interest |
Academic |
2 years following the last publication of research results |
Clinical data |
No |

